Analgesia News and Research RSS Feed - Analgesia News and Research

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). [More]
FDA approves additional manufacturing suite for Pacira’s EXPAREL

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured. [More]
New drug multiplies analgesic effect of opioids without increasing constipation

New drug multiplies analgesic effect of opioids without increasing constipation

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine. [More]
Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. [More]

Conditioned pain modulation decreases activity in human spinal cord, say researchers

Researchers have demonstrated that conditioned pain modulation (CPM), a measure of the brain's ability to regulate pain, decreases activity in the human spinal cord as visible via functional magnetic resonance imaging (fMRI). [More]
Novel scaffold protein regulates mu opioid receptor induced signaling activation

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Researchers found initial confirmation that a novel scaffold protein previously unassociated with the mu opioid receptor (MOR) regulates MOR-induced signaling activation. [More]
AcelRx Pharmaceuticals announces financial results for fourth quarter and full year 2013

AcelRx Pharmaceuticals announces financial results for fourth quarter and full year 2013

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013. [More]

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint. [More]

Study reveals spinal manipulation therapy reduces severity of pain in many patients

The lessening of pain sensitivity achieved with spinal manipulation therapy (SMT) occurs as a result of the treatment and not as much from a placebo effect caused by the expectation of receiving SMT, according to a study published in The Journal of Pain. [More]
Opiate use alters activity of specific protein needed for normal functioning of brain's reward center

Opiate use alters activity of specific protein needed for normal functioning of brain's reward center

Identifying the specific pathways that promote opioid addiction, pain relief, and tolerance are crucial for developing more effective and less dangerous analgesics, as well as developing new treatments for addiction. [More]
FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults. [More]

Patient controlled analgesia not equivalent to epidural analgesia for pain relief during labor

In a study to be presented on Feb. 7 at 1:30 p.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting-, in New Orleans, researchers will report findings which suggest remifentanil patient controlled analgesia is not equivalent to epidural analgesia for pain, pain appreciation scores, and overall satisfaction in women who request for pain relief during labor. [More]

Clonidine before surgery may control post-surgical pain and child's anxiety

Managing a child's pain and distress after surgery is an essential part of recovery. However, using strong painkilling medications post-surgery can put kids at risk for side effects and other complications. [More]

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults. [More]

Perioperative analgesia may improve prostate cancer outcomes

Neuraxial analgesia added to general anesthesia for radical retropubic prostatectomy may lead to improved oncologic outcomes in prostate cancer, US researchers have found. [More]

Smiths Medical gets FDA clearance to market CADD-Solis system with PIB and PCA delivery in the US

Smiths Medical, a leading global medical device manufacturer, announced today it has received FDA 510(k) clearance to market its CADD-Solis pain management system version 3.0 with Programmed Intermittent Bolus and Patient Controlled Analgesics delivery in the United States. The new customizable, infusion system will help healthcare providers overcome challenges in maintaining effective epidural analgesia during labor and delivery or with post-operative pain management. [More]

Satisfaction can be enhanced by improving quality of information received by day-surgery patients

Satisfaction expressed by day-surgery patients can be enhanced by improving the quality of information they receive, and also help assure successful post-operative recovery without the need for outpatient follow-up, according to research reported in the Journal of Healthcare Quality, the peer reviewed publication of the National Association for Healthcare Quality (NAHQ), www.nahq.org. [More]

Study reports increased risk of death in patients receiving anesthesia drug etomidate for surgery

Patients receiving the widely used anesthesia drug etomidate for surgery may be at increased risk or mortality and cardiovascular events, according to a study in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society. [More]

Global intravenous access devices market expected to reach $46.5 billion by 2019

According to a new market report published by Transparency Market Research "Intravenous Access Devices Market (Intravenous Needles, Intravenous Catheters and Intravenous Infusion Pumps) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,"in 2012, the global intravenous access devices market was valued at USD 27.2 billion and is expected to grow at a CAGR of 7.8% during the forecast period of 2013 to 2019 to reach a market value of USD 46.5 billion by 2019. [More]
Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer. [More]